Multinational randomised controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25142273

Enrollment

891

Registered

2002-05-09

Start date

1999-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Musculoskeletal Diseases Arthropathies

Interventions

1. Etoricoxib 90 mg once daily, naproxen 500 mg twice daily 2. Placebo for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with rheumatoid arthritis 2. Aged greater than or equal to 18 years

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Costa Rica, France, Germany, Greece, Hong Kong, Israel, Italy, Lithuania, Mexico, New Zealand, Peru, Romania, Singapore, Slovenia, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States of America, Venezuela

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026